Evotec SE Stock

Description Evotec

Evotec is a German-based biotechnology company that specializes in drug discovery and development. It was founded in 1993 and is currently headquartered in Hamburg, Germany.

The company’s business revolves around its two core segments of drug discovery and development services. Under its drug discovery services segment, Evotec provides a range of drug discovery solutions to clients across various therapeutic areas such as oncology, neuroscience, metabolic diseases, and inflammation. These services often include compound libraries, screening technologies, hit-to-lead optimization, and candidate selection.

On the other hand, its development services segment offers drug development solutions to clients that range from preclinical to Phase III clinical trials. This includes project management, clinical data management, and statistical analysis.

Evotec also has a portfolio of drug discovery programs that are aimed at developing potential treatments for diseases such as Alzheimer's and Parkinson's disease, diabetes, and cancer. The company’s innovation and research have enabled it to collaborate with leading pharmaceutical companies such as Bayer, Sanofi, and Boehringer Ingelheim.

In terms of its financial performance, Evotec has seen steady growth in recent years. In 2020, the company reported total revenues of €566.5 million, an increase of 24% compared to the previous year. Overall, the company has a strong reputation in the biotechnology industry, and its focus on drug discovery and development has made it an attractive option for investors looking to capitalize on exciting developments in the field.

Competitors of Evotec

Evotec is a German biotech company that operates in the pharmaceutical industry, specifically in the areas of drug discovery and development. The company has a unique business model that involves partnerships with pharmaceutical companies and academic institutions to accelerate drug development programs.

The main competitors of Evotec include:

1. Gilead Sciences: an American biotech company that focuses on developing and commercializing drugs for the treatment of viral infections, cancer, inflammatory, and respiratory diseases.

2. Biogen: an American biotech company that specializes in the development and commercialization of drugs for neurological and neurodegenerative diseases, such as Alzheimer's and Parkinson's.

3. Roche: a Swiss multinational healthcare company that operates in the pharmaceutical and biotech industries. Roche develops and markets innovative medicines and diagnostic tests in various therapeutic areas, including oncology, immunology, and neurology.

4. Novartis: another Swiss multinational healthcare company that operates in the pharmaceutical and biotech industries. Novartis develops and markets innovative medicines and generic drugs in various therapeutic areas, including oncology, immunology, and cardiovascular diseases.

All these companies have extensive resources and knowledge in drug discovery and development, making them formidable competitors for Evotec. However, Evotec's unique business model, which relies on partnerships and collaborations, gives it an advantage in terms of flexibility and speed in drug development programs.

Suppliers of Evotec

Evotec is a German drug discovery and development company that operates in the pharmaceutical industry. As such, its most important suppliers are likely to be those who provide the materials and equipment necessary for drug research and manufacturing. These suppliers may include:

1. Chemical and reagent suppliers: Evotec requires a wide range of chemicals and reagents for its drug discovery and preclinical research activities. These may include organic and inorganic compounds, buffers, purification resins, and other essential materials.

2. Laboratory equipment suppliers: To conduct its research, Evotec requires a range of laboratory equipment such as pipettes, centrifuges, spectrometers, and other specialized scientific instruments. These suppliers may provide Evotec with everything from high-throughput screening systems to single-use bioreactors for cell culture.

3. Contract research organizations (CROs): While not technically suppliers, CROs are an important partner for Evotec. These organizations provide highly specialized services such as bioassay development, ADME-Tox testing, and preclinical animal studies that are critical to the drug discovery and development process.

4. Service providers: Evotec likely also relies on a range of service providers for various aspects of its business operations. These may include logistics providers for shipping and handling research materials, consulting firms for regulatory affairs or clinical trial design, and IT vendors for data management and analysis.

Overall, Evotec's ability to source materials, equipment, and services from reliable and cost-effective suppliers is critical to its continued success in the highly competitive pharmaceutical industry.